The Invesco Perpetual Children's Fund aims to achieve longer term capital growth through a portfolio of investments in UK companies. In pursuing this objective, the fund managers may include investments that they consider appropriate which include transferable securities, money market instruments, warrants, collective investment schemes, deposits and other permitted investments and transactions as detailed in Appendix 2 of the most recent Prospectus.
Name | % Net Assets |
---|---|
BT | 6.8% |
BP | 5.7% |
GlaxoSmithKline | 5.7% |
Rentokil Initial | 4.9% |
BAE Systems | 4.9% |
Imperial Tobacco | 4.6% |
BG | 4.4% |
AstraZeneca | 4.2% |
Legal & General | 3.8% |
Vodafone | 3.2% |
Key | % Net Assets |
---|---|
BT | 6.8% |
BP | 5.7% |
GlaxoSmithKline | 5.7% |
Rentokil Initial | 4.9% |
Other | 76.9% |
Date | 21-Nov-2024 |
---|---|
NAV | 544.74p |
Currency | GBP |
Change | 0.38p |
% | 0.07% |
YTD change | 53.57p |
YTD % | 10.91% |
Fund Inception | 20/04/1988 |
---|---|
Fund Manager | Martin Walker |
TER | 1.73 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | £100 |
Savings | £20 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.72% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.11 |
You are here: research